AbbVie Inc. Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Biotechnology | Market Cap: ₹3.9L Cr
- AbbVie raised full-year adjusted EPS guidance to $14.08-$14.28, reflecting strong momentum. - AbbVie raised its full-year adjusted earnings per share (EPS) guidance to a range of $14.08 to $14.28, up by $0.12 from previous guidance.
From AbbVie Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹218.63
Market Cap
₹3.9L Cr
P/E Ratio
104.0
Revenue Rank
Margin Rank
How does AbbVie Inc. rank in Biotechnology?
Compare AbbVie Inc. against every Biotechnology company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 2- →AbbVie raised full-year adjusted EPS guidance to $14.08-$14.28, reflecting strong momentum.
- →Total net revenues expected at approximately $67.3 billion, up $300 million from prior forecast.
- →Skyrizi global revenues projected at $21.6 billion, up $100 million, driven by psoriatic and IBD growth.
- →Rinvoq global sales forecast at $10.2 billion, up $100 million with strong performance in rheumatoid and gastro indications.
- →Neuroscience segment revenues expected to reach $12.6 billion, up $100 million due to portfolio momentum.
- →Immunology and neuroscience are delivering high double-digit growth, many assets growing north of 20%.
- →Skyrizi and Rinvoq expected to exceed peak sell-side consensus forecasts.
- →Oncology pipeline assets and obesity programs contribute to growth outlook.
- →AbbVie plans ongoing business development to drive long-term growth, with strong financial capacity.
- →Emphasis on best-in-class efficacy and convenient dosing regimens to capture market share.
📈 Profitability & Margins
Rank 3- →AbbVie raised its full-year adjusted earnings per share (EPS) guidance to a range of $14.08 to $14.28, up by $0.12 from previous guidance.
- →First quarter adjusted EPS exceeded guidance by $0.07, coming in at $2.65.
- →Adjusted operating margin ratio is expected to be approximately 47.5% of sales for the full year, including a 1% unfavorable impact from acquired IP R&D expenses.
- →Full-year adjusted gross margin is forecasted above 84% of sales.
- →Adjusted R&D expense is projected at approximately $9.7 billion, and adjusted SG&A expense at approximately $14.2 billion.
- →Second-quarter adjusted operating margin ratio is anticipated around 50% with EPS guidance between $3.74 and $3.78.
- →AbbVie expects top-tier growth with significant contributions from key products like Skyrizi and Rinvoq, both projected to exceed sell-side peak consensus forecasts.
🏗️ Capital Expenditure Plans
Yes- →AbbVie announced several new manufacturing site constructions as part of a $100 billion commitment to U.S. R&D and capital investments over the next decade.
- →$1.4 billion investment to build a pharmaceutical manufacturing campus in North Carolina.
- →$380 million investment for two new plants in North Chicago.
- →These strategic investments aim to strengthen AbbVie’s ability to produce medical breakthroughs in immunology, neuroscience, oncology, and obesity.
- →AbbVie is investing at record levels in the business to support long-term growth and pipeline development.
- →The company maintains strong financial flexibility to pursue compelling business development and return capital to shareholders.
💰 Fundraising & Capital Structure
No information- →There is no mention of plans for new fundraising through debt or equity in the provided transcript.
- →AbbVie highlights strong financial health and ample financial capacity to pursue business development.
- →The company has reduced its adjusted net interest expense forecast by $100 million due to favorable debt issuance rates.
- →Capital allocation priorities focus on investing in the business, pursuing business development, and returning capital to shareholders via dividends.
- →No indications of issuing new equity or raising debt beyond existing financial strategies were stated.
📋 Order Book & Pipeline
YesKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
Frequently Asked Questions
What were AbbVie Inc. Q2 FY26 results?
- AbbVie raised full-year adjusted EPS guidance to $14.08-$14.28, reflecting strong momentum. - AbbVie raised its full-year adjusted earnings per share (EPS) guidance to a range of $14.08 to $14.28, up by $0.12 from previous guidance.
What is AbbVie Inc. share price analysis?
AbbVie Inc. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 104.0 with a market cap of $386,274. Investors should review the full earnings analysis for detailed insights.
Is AbbVie Inc. planning capital expenditure?
- AbbVie announced several new manufacturing site constructions as part of a $100 billion commitment to U.S.
Keep AbbVie Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.